Research

New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors




We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.


This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.


The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.



Latest In Research

01/23
2018

Merck’s Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial

From BioSpace:                                         Merck’s Keytruda has done it again. The company reported data from its Phase III KEYNOTE-189 clinical trial of Keytruda in combination with pemetrexed (Alimta…

01/23
2018

FDA Expands Afatinib’s Approval for Lung Cancer

From OncLive The FDA has expanded the frontline indication for afatinib (Gilotrif) to include the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor uncommon EGFR alterations in L861Q, G719X, a…

01/23
2018

Many Elderly Lung Cancer Patients Receive No Treatment

From Modern Medicine Network Nearly two-thirds of older patients with stage III lung cancer do not receive any treatment, according to a new study. Although more than one-third of new lung cancers are diagnosed in patients age 75 years an…

01/23
2018

Seeking Consensus Amid Abundant New Lung Cancer Data

From MedScape Hello. I'm Mark Kris from Memorial Sloan Kettering, reporting on the recent 12th Annual New York Lung Cancers Symposium held here in New York City on November 11. We gathered experts and physicians treating lung cancer in th…

01/23
2018

Targeted Therapies Convey Survival Benefit in Patients With Lung Cancer

From Targeted Oncology Regardless of smoking history, patients with cancer of the lung harboring specific genetic alterations who were treated with targeted therapies experienced longer survival than those patients who did not receive target…



Read More